Compositions Containing a Pharmacophore with Selectivity to Diseased Tissue and Methods of Making Same

A method of treating an individual suffering from a disease, the method comprising:

• a) providing a targeting peptide comprising a sequence substantially identical to a CAR pharmacophore, the sequence selected from the group consisting of SEQ ID NO:16-SEQ ID NO:33, or a variant thereof;
• (b) providing at least one therapeutic molecule which conveys a measureable therapeutic benefit to a disease selected from the group consisting of pulmonary diseases, pulmonary hypertension, interstitial lung disease, acute lung injury, acute respiratory distress syndrome, asthma, sepsis, septic shock, infection, sarcoidosis of the lung, pulmonary manifestations of connective tissue diseases, including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, and polymyositis, dennatomyositis, bronchiectasis, asbestosis, berylliosis, silicosis, Histiocytosis X, pneumonia, pneumotitis, smoker's lung, bronchiolitis obliterans, pulmonary fibrosis, other fibrotic diseases such as myocardial infarction, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, pneumoconiosis, nephrogenic systemic fibrosis, scar formation, keloid, arthrofibrosis, adhesive capsulitis, radiation fibrosis, fibrocystic breast condition, liver cirrhosis, hepatitis, liver fibrosis, nonalcoholic fatty liver disease, acute liver failure, nonalcoholic steatohepatitis, sarcoidosis of the lymph nodes, or other organs;
• inflammatory bowel disease, Crohn's disease, cachexia, chronic kidney disease, acute kidney injury, acute renal failure, polycystic kidney disease, ulcerative colitis, primary biliary cirrhosis, pancreatitis, interstitial cystitis, chronic obstructive pulmonary disease, atherosclerosis, ischemic heart disease, vasculitis, neoplastic/metastatic/oncological diseases (including cancer), pneumoconiosis, autoimmune diseases, angiogenic diseases, wound healing, infections, trauma injuries and systemic connective tissue diseases including systemic lupus erythematosus, rheumatoid arthritis scleroderma, polymyositis, dermatomyositis, cystic fibrosis, erectile dysfunction, α1-antitrypsin deficiency, diabetes, diseases characterized by high heparanase levels, neuroinflammatory conditions, stroke, CNS degenerative diseases, such as Alzheimer's Disease, Parkinson's disease (PD), Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, hypoxia, aging brain, wet macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, glioblastoma, and senescence-related diseases;
• c) co-administering a composition comprising a) and b) to an individual in need thereof;
• and
• d) measuring a therapeutic benefit to the individual.

A conjugate for treating an individual suffering from a disease, wherein the peptide is comprised of:

• a) at least one peptide containing an amino acid segment with the sequence of SEQ ID NOs:
• 1-8, 12, and 16-33, related amino acid sequences, or the CAR pharmacophore;
• and
• b) a moiety linked to the peptide of a).

A conjugate for diagnosing an individual suffering from a disease, wherein the peptide is comprised of:

• a) at least one peptide containing an amino acid segment with the sequence of SEQ ID NOs:
• 1-8, 12, and 16-33, related amino acid sequences, or the CAR pharmacophore;
• and
• b) a moiety linked to the peptide of a).